Neurogene’s (NGNE) Outperform Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Neurogene (NASDAQ:NGNE) in a research note issued to investors on Tuesday,RTT News reports. William Blair also issued estimates for Neurogene’s Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS, Q1 2026 earnings at ($1.18) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS, Q4 2026 earnings at ($1.16) EPS and FY2026 earnings at ($4.60) EPS.

Separately, HC Wainwright cut their target price on shares of Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $59.80.

Neurogene Stock Performance

Shares of NGNE stock opened at $15.33 on Tuesday. Neurogene has a 52 week low of $13.47 and a 52 week high of $74.49. The company has a 50-day simple moving average of $16.92 and a 200 day simple moving average of $28.96. The company has a market capitalization of $227.73 million, a price-to-earnings ratio of -3.59 and a beta of 1.01.

Neurogene (NASDAQ:NGNE) last announced its earnings results on Monday, March 24th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.05. The business had revenue of $0.93 million for the quarter. Sell-side analysts forecast that Neurogene will post -4.27 EPS for the current year.

Insider Activity

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the completion of the transaction, the chief financial officer now directly owns 72,343 shares in the company, valued at $1,225,490.42. The trade was a 5.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 9.92% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP grew its position in Neurogene by 18.7% in the fourth quarter. Wellington Management Group LLP now owns 21,717 shares of the company’s stock worth $496,000 after acquiring an additional 3,427 shares in the last quarter. Vestal Point Capital LP bought a new position in shares of Neurogene during the 4th quarter valued at about $1,829,000. Squarepoint Ops LLC raised its holdings in shares of Neurogene by 250.0% during the 4th quarter. Squarepoint Ops LLC now owns 17,431 shares of the company’s stock valued at $398,000 after buying an additional 12,451 shares in the last quarter. Two Sigma Investments LP bought a new stake in Neurogene in the 4th quarter worth approximately $472,000. Finally, RTW Investments LP boosted its stake in Neurogene by 18.9% in the fourth quarter. RTW Investments LP now owns 1,350,256 shares of the company’s stock worth $30,867,000 after buying an additional 215,000 shares in the last quarter. 52.37% of the stock is currently owned by institutional investors.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.